SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer ...
November 30 2018 - 8:30AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of novel cancer immunotherapies for a broad range
of cancer indications, today announced that further correlative
data from the Phase 2b trial of nelipepimut-S (NPS, NeuVax™) in
combination with trastuzumab (Herceptin®) for the treatment of
women with triple-negative breast cancer (TNBC) will be presented
in a poster presentation at the 2018 San Antonio Breast Cancer
Symposium (SABCS), taking place December 4-8, 2018 in San Antonio,
TX. The data will include efficacy results from analysis of key
predefined subgroups and the difference in the patterns of disease
relapse between the active (NPS plus trastuzumab) versus the
control (trastuzumab) arms.
Details for the presentation are as follows:
Title: Subgroups analysis of a multicenter,
prospective, randomized, blinded phase 2b trial of trastuzumab +
nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence
in breast cancer patients
Poster Session 2: Treatment: Immunotherapy
(clinical)
Poster Hall Location: Hall 1
Poster Hall Hours: Thursday, December 6, 2018;
8:30 – 10:00 am ET
Abstract ID: P2-09-01
SELLAS previously announced that the full dataset, as well as
correlations between clinical response and HLA type, from the Phase
2b trial of nelipepimut-S in combination with trastuzumab were
presented in an oral presentation at the 2018 Annual Meeting of the
European Society for Medical Oncology (ESMO) on October 22, 2018 in
Munich, Germany, and in a poster presentation at the 2018 Society
for Immunotherapy of Cancer (SITC) Annual Meeting on November 9 and
10, 2018 in Washington, D.C., respectively.
About SELLAS Life Sciences Group, Inc.
SELLAS is a clinical-stage biopharmaceutical company focused on
the development of novel cancer immunotherapeutics for a broad
range of cancer indications. SELLAS’ lead product candidate,
galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering
Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is
present in an array of tumor types. GPS has potential as a
monotherapy or in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS has
Phase 3 clinical trials planned for GPS in two indications, acute
myeloid leukemia (AML) and malignant pleural mesothelioma (MPM),
and is also developing GPS as a potential treatment for multiple
myeloma (MM) and ovarian cancer. SELLAS plans to study GPS in up to
four additional indications. SELLAS has received Orphan Drug (or
Medicinal Product) designations for GPS from both the U.S. Food
& Drug Administration (FDA) and the European Medicines Agency
(EMA) for AML, MPM, and MM. GPS also received Fast Track
designation for AML, MPM and MM from the FDA. SELLAS’ second
product candidate, NeuVax™ (nelipepimut-S), is a HER2-directed
cancer immunotherapy being investigated for the prevention of the
recurrence of breast cancer after standard of care treatment in the
adjuvant setting. NeuVax™ has received Fast Track status
designation by FDA for the treatment of patients with early stage
breast cancer with low to intermediate HER2 expression, otherwise
known as HER2 1+ or 2+, following standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contacts:
Will O’ConnorStern Investor Relations,
Inc.212-362-1200ir@sellaslife.com
David Moser, JDSellas Life Sciences
Group813-864-2571info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024